(5) Now in Dec 2017 OMHE announced its plan already in motion to create a drug candidate compelling to Big Pharma, development of cannabidiol pain treatment therapeutic & medicine and filing of FDA registration by employing an FDA regulations-savvy, ‘fast-track’ pipeline strategy. CLICK HERE TO READ DEC 2017 FDA REGISTRATION UPDATE
Based on four decades of exemplary care, Omni Health has started the process of reformulating its most successful proprietary formularies to include cannabidiol (CBD) and commence itsFDA Medical Devices registration for topical pain analgesic. It is Omni Health’s intent to capitalize on a significant potential for cannabinoid bio therapeutics to transform the treatment of chronic pain and other debilitating conditions, and bring a product to the market with a strong demand and reimbursable under government payors and major insurance plans.
OMHE PPS Ready to Rise to $1
Made Thousands into Millions..Now in Tens of Millions
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.